Introduction: Uterine fibroids (UFs), also known as leiomyomas, are the most common benign gynecological tumors. Currently, morcellation is discouraged due to the risk of disseminating undetected malignancies. This study aimed to update the prevalence data on occult malignancies in surgeries for suspected benign uterine lesions and analyze the impact of treatment strategies on the survival outcomes in patients with occult malignancy. Methods: Five English-language literature databases were systematically searched up to July 25, 2024, for studies reporting the incidence of occult malignancies in patients with suspected UFs and their survival outcomes. The study was preregistered on PROSPERO (CRD42024580233). Results: A total of 34 studies were included in the analysis. The pooled incidence of occult malignancies, calculated using a random-effects model, was 2.88 (2.10–3.94) per 1,000 individuals. Significant regional variations were observed in the subgroup comparisons (p < 0.01). Morcellation did not significantly affect progression-free survival (PFS) (hazard ratio [HR]: 1.26, 95% confidence interval [CI]: 0.86–1.84, p = 0.240) or overall survival (OS) (HR: 1.13, 95% CI: 0.70–1.82, p = 0.614). Pooled analysis of HR revealed that chemotherapy significantly improved PFS (HR: 0.49; 95% CI: 0.32–0.77; p = 0.002) and OS (HR: 0.49; 95% CI: 0.28–0.87; p = 0.015). Conclusions: The incidence of occult malignancies in women undergoing hysterectomy or myomectomy for benign conditions is approximately 2.88 per 1,000 individuals. Morcellation does not impact survival outcomes, whereas adjuvant chemotherapy provides a survival benefit. Further well-designed clinical trials are required to validate these findings.

Uterine fibroids (UFs) are a common health issue among women; however, they can occasionally present a hidden danger. We investigated the potential for these fibroids to represent an occult malignancy. We further assessed how various treatment options could impact patient outcomes following surgery. We reviewed the medical literature to determine the incidence of occult malignancy and factors influencing patient survival. Thirty-four studies met the criteria for inclusion in our analysis. Our findings indicate that approximately 3 of every 1,000 women who undergo surgery for presumed benign fibroids may, in fact, have an occult malignancy. Geographic location may significantly influence the likelihood of having an occult malignancy. The use of morcellation during surgery does not appear to significantly impact postoperative survival outcomes. Additionally, women diagnosed with occult malignancies have improved survival outcomes when treated with chemotherapy. In conclusion, although the likelihood of occult malignancy in UFs is rare, awareness remains crucial. Chemotherapy can significantly impact patient prognosis. Further research is necessary to validate our findings.

1.
Yang
Q
,
Ciebiera
M
,
Bariani
MV
,
Ali
M
,
Elkafas
H
,
Boyer
TG
, et al
.
Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment
.
Endocr Rev
.
2022
;
43
(
4
):
678
719
.
2.
Silberzweig
JE
,
Powell
DK
,
Matsumoto
AH
,
Spies
JB
.
Management of uterine fibroids: a focus on uterine-sparing interventional techniques
.
Radiology
.
2016
;
280
(
3
):
675
92
.
3.
Ali
M
,
Ciebiera
M
,
Wlodarczyk
M
,
Alkhrait
S
,
Maajid
E
,
Yang
Q
, et al
.
Current and emerging treatment options for uterine fibroids
.
Drugs
.
2023
;
83
(
18
):
1649
75
.
4.
Shazly
SA
,
Laughlin-Tommaso
SK
,
Breitkopf
DM
,
Hopkins
MR
,
Burnett
TL
,
Green
IC
, et al
.
Hysteroscopic morcellation versus resection for the treatment of uterine cavitary lesions: a systematic review and meta-analysis
.
J Minim Invasive Gynecol
.
2016
;
23
(
6
):
867
77
.
5.
Ren
F
,
Huang
G
,
Wang
X
,
Li
X
,
Cai
J
.
Comparison of hysteroscopic morcellation versus resectoscopy in treatment of patients with endometrial lesions: a meta-analysis
.
Med Sci Monit
.
2022
;
28
:
e936771
.
6.
Wagenaar
LP
,
Hamerlynck
TW
,
Radder
CM
,
Peters
LW
,
Weyers
S
,
Schoot
BC
, et al
.
Hysteroscopic morcellation vs. curettage for removal of retained products of conception: a multicenter randomized controlled trial
.
Fertil Steril
.
2023
;
120
(
6
):
1243
51
.
7.
Wong
M
,
De Wilde
RL
,
Isaacson
K
.
Reducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgery
.
Arch Gynecol Obstet
.
2018
;
297
(
2
):
285
93
.
8.
Ricci
S
,
Stone
RL
,
Fader
AN
.
Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation
.
Gynecol Oncol
.
2017
;
145
(
1
):
208
16
.
9.
Zullo
F
,
Venturella
R
,
Raffone
A
,
Saccone
G
.
In-bag manual versus uncontained power morcellation for laparoscopic myomectomy
.
Cochrane Database Syst Rev
.
2020
;
5
:
CD013352
.
10.
Elizabeth
A
.
Pritts. Leiomyosarcoma: implications for the treatment of fibroids
. In:
Metwally
M
,
Li
T-C
, editors.
Modern management of uterine fibroids
.
Cambridge
:
Cambridge University Press
;
2020
. p.
155
64
.
11.
Pritts
EA
,
Parker
WH
,
Brown
J
,
Olive
DL
.
Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review
.
J Minim Invasive Gynecol
.
2015
;
22
(
1
):
26
33
.
12.
Rosenbaum
L
.
N-of-1 policymaking--tragedy, trade-offs, and the demise of morcellation
.
N Engl J Med
.
2016
;
374
(
10
):
986
90
.
13.
Stang
A
.
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
.
Eur J Epidemiol
.
2010
;
25
(
9
):
603
5
.
14.
Peters
JL
,
Sutton
AJ
,
Jones
DR
,
Abrams
KR
,
Rushton
L
.
Comparison of two methods to detect publication bias in meta-analysis
.
JAMA
.
2006
;
295
(
6
):
676
80
.
15.
Cao
Y
,
Shi
H
,
Zhuo
X
.
Occult endometrial cancer in women undergoing hysterectomy for benign indications: a retrospective cohort study in a tertiary hospital in China
.
Arch Gynecol Obstet
.
2024
;
310
(
2
):
1215
22
.
16.
Yang
J
,
Yang
J
,
Cao
D
,
Pan
L
,
Wu
M
,
Xiang
Y
.
Management of stage I occult uterine leiomyosarcoma: effects of morcellation, second-look surgery, and adjuvant treatments on survival
.
Ann Transl Med
.
2022
;
10
(
2
):
127
.
17.
Surace
A
,
Bau
MG
,
Privitera
S
,
Botta
G
,
Danese
S
,
Plazzotta
C
, et al
.
Risk of unexpected uterine leiomyosarcoma during laparoscopic procedures: experience from a single tertiary institute in Italy
.
Int J Gynaecol Obstet
.
2022
;
156
(
2
):
236
9
.
18.
Zhang
G
,
Yu
X
,
Zhu
L
,
Fan
Q
,
Shi
H
,
Lang
J
.
Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid
.
BMC Cancer
.
2020
;
20
(
1
):
514
.
19.
Wang
L
,
Li
S
,
Zhang
Z
,
Jia
J
,
Shan
B
.
Prevalence and occult rates of uterine leiomyosarcoma
.
Medicine
.
2020
;
99
(
33
):
e21766
.
20.
Yorganci
A
,
Meydanli
MM
,
Kadioglu
N
,
Taskin
S
,
Kayikcioglu
F
,
Altin
D
, et al
.
Incidence and outcome of occult uterine sarcoma: a multi-centre study of 18604 operations performed for presumed uterine leiomyoma
.
J Gynecol Obstet Hum Reprod
.
2020
;
49
(
1
):
101631
.
21.
Zheng
Z
,
Han
ZH
,
Li
ZT
,
Wu
XH
.
The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma
.
Eur J Gynaecol Oncol
.
2019
;
40
:
977
81
.
22.
Xu
X
,
Lin
H
,
Wright
JD
,
Gross
CP
,
Boscoe
FP
,
Hutchison
LM
, et al
.
Association between power morcellation and mortality in women with unexpected uterine cancer undergoing hysterectomy or myomectomy
.
J Clin Oncol
.
2019
;
37
(
35
):
3412
24
.
23.
Wu
CQ
,
Woo
LY
,
Giede
KC
,
Thiel
J
,
Karreman
E
,
Rattray
DD
.
Occult leiomyosarcomas in a Canadian Province: a retrospective cohort study
.
J Obstet Gynaecol Can
.
2019
;
41
(
1
):
46
51
.
24.
Multinu
F
,
Casarin
J
,
Tortorella
L
,
Huang
Y
,
Weaver
A
,
Angioni
S
, et al
.
Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study
.
Am J Obstet Gynecol
.
2019
;
220
(
2
):
179.e1
e10
.
25.
Lentz
SE
,
Zaritsky
E
,
Tucker
LY
,
Lee
C
,
Lazo
IM
,
Niihara
A
, et al
.
Prediction of occult uterine sarcoma before hysterectomy for women with leiomyoma or abnormal bleeding
.
J Minim Invasive Gynecol
.
2020
;
27
(
4
):
930
7.e1
.
26.
Beyan
E
,
Kanmaz
AG
,
Inan
AH
,
Karatasli
V
,
Tutar
SO
,
Alan
M
, et al
.
Evaluation of occult uterine leiomyosarcomas
.
Ginekol Pol
.
2019
;
90
(
8
):
433
7
.
27.
Wilkie
GL
,
Reus
E
,
Leung
K
,
Bradford
L
,
Manning
MJ
,
Moore Simas
TA
.
Occult malignancy incidence and preoperative assessment in hysterectomies with morcellation
.
J Gynecol Surg
.
2018
;
34
(
1
):
18
26
.
28.
Parsons
LHP
,
Pedersen
R
,
Richardson
DL
,
Kho
KA
.
The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications
.
Eur J Obstet Gynecol Reprod Biol
.
2018
;
223
:
108
12
.
29.
Ludwin
A
,
Gawron
I
,
Pitynski
K
.
Occult uterine leiomyosarcoma in women undergoing abdominal and minimally invasive surgeries for myomas
.
Ginekol Pol
.
2018
;
89
(
10
):
546
52
.
30.
Desai
VB
,
Wright
JD
,
Schwartz
PE
,
Jorgensen
EM
,
Fan
L
,
Litkouhi
B
, et al
.
Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications
.
Obstet Gynecol
.
2018
;
131
(
4
):
642
51
.
31.
Chen
Q
,
Shi
H
,
Lu
W
,
Lu
B
.
Unexpected uterine sarcomas in 4478 patients with electric power morcellation for leiomyomas
.
Eur J Obstet Gynecol Reprod Biol
.
2018
;
230
:
85
9
.
32.
Lange
S
,
Pluchino
N
,
Fehlmann
A
,
Marci
R
,
Boukrid
M
,
Jazia
IB
, et al
.
Prevalence of undiagnosed uterine leiomyosarcoma in women undergoing hysterectomy or myomectomy for benign indications
.
Eur J Obstet Gynecol Reprod Biol
.
2017
;
216
:
239
44
.
33.
Bojahr
B
,
De Wilde
RL
,
Tchartchian
G
.
Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH)
.
Arch Gynecol Obstet
.
2015
;
292
(
3
):
665
72
.
34.
Wasson
M
,
Magtibay
P
2nd
,
Magtibay
P
3rd
,
Magrina
J
.
Incidence of occult uterine malignancy following vaginal hysterectomy with morcellation
.
J Minim Invasive Gynecol
.
2017
;
24
(
4
):
665
9
.
35.
Skorstad
M
,
Kent
A
,
Lieng
M
.
Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study
.
Acta Obstet Gynecol Scand
.
2016
;
95
(
9
):
984
90
.
36.
Rodriguez
AM
,
Asoglu
MR
,
Sak
ME
,
Tan
A
,
Borahay
MA
,
Kilic
GS
.
Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study
.
Eur J Obstet Gynecol Reprod Biol
.
2016
;
197
:
31
5
.
37.
Raine-Bennett
T
,
Tucker
LY
,
Zaritsky
E
,
Littell
RD
,
Palen
T
,
Neugebauer
R
, et al
.
Occult uterine sarcoma and leiomyosarcoma: incidence of and survival associated with morcellation
.
Obstet Gynecol
.
2016
;
127
(
1
):
29
39
.
38.
Kho
KA
,
Lin
K
,
Hechanova
M
,
Richardson
DL
.
Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications
.
Obstet Gynecol
.
2016
;
127
(
3
):
468
73
.
39.
Paul
PG
,
Rengaraj
V
,
Das
T
,
Garg
R
,
Thomas
M
,
Khurd
AS
.
Uterine sarcomas in patients undergoing surgery for presumed leiomyomas: 10 years' experience
.
J Minim Invasive Gynecol
.
2016
;
23
(
3
):
384
9
.
40.
Gao
Z
,
Li
L
,
Meng
Y
.
A retrospective analysis of the impact of myomectomy on survival in uterine sarcoma
.
PLoS One
.
2016
;
11
(
2
):
e0148050
.
41.
Zhang
J
,
Li
T
,
Zhang
J
,
Zhu
L
,
Lang
J
,
Leng
J
.
Clinical characteristics and prognosis of unexpected uterine sarcoma after hysterectomy for presumed myoma with and without transvaginal scalpel morcellation
.
Int J Gynecol Cancer
.
2016
;
26
(
3
):
456
63
.
42.
Yuk
JS
,
Kim
LY
,
Kim
SH
,
Lee
JH
.
The incidence of unexpected uterine malignancy in women undergoing hysterectomy for a benign condition: a national population-based study
.
Ann Surg Oncol
.
2016
;
23
(
12
):
4029
34
.
43.
Mao
J
,
Pfeifer
S
,
Zheng
XE
,
Schlegel
P
,
Sedrakyan
A
.
Population-based estimates of the prevalence of uterine sarcoma among patients with leiomyomata undergoing surgical treatment
.
JAMA Surg
.
2015
;
150
(
4
):
368
70
.
44.
Zhao
WC
,
Bi
FF
,
Li
D
,
Yang
Q
.
Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases
.
Onco Targets Ther
.
2015
;
8
:
2943
8
.
45.
Brohl
AS
,
Li
L
,
Andikyan
V
,
Obican
SG
,
Cioffi
A
,
Hao
K
, et al
.
Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma
.
Oncologist
.
2015
;
20
(
4
):
433
9
.
46.
Mahnert
N
,
Morgan
D
,
Campbell
D
,
Johnston
C
,
As-Sanie
S
.
Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications
.
Obstet Gynecol
.
2015
;
125
(
2
):
397
405
.
47.
Wright
JD
,
Tergas
AI
,
Burke
WM
,
Cui
RR
,
Ananth
CV
,
Chen
L
, et al
.
Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation
.
Obstetrical Gynecol Surv
.
2014
;
69
(
11
):
653
4
.
48.
Lieng
M
,
Berner
E
,
Busund
B
.
Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women
.
J Minim Invasive Gynecol
.
2015
;
22
(
3
):
410
4
.
49.
Parker
WH
,
Pritts
EA
,
Olive
DL
.
What is the future of open intraperitoneal power-morcellation of fibroids
.
Clin Obstet Gynecol
.
2016
;
59
(
1
):
73
84
.
50.
Stentz
NC
,
Cooney
LG
,
Sammel
M
,
Shah
DK
.
Changes in myomectomy practice after the U.S. Food and Drug administration safety communication on power morcellation
.
Obstet Gynecol
.
2017
;
129
(
6
):
1007
13
.
51.
Pritts
EA
.
The prevalence of occult leiomyosarcoma in women undergoing presumed fibroid surgery and outcomes after morcellation
.
Curr Opin Obstet Gynecol
.
2018
;
30
(
1
):
81
8
.
52.
Laban
M
,
El-Swaify
ST
,
Ali
SH
,
Refaat
MA
,
Sabbour
M
,
Farrag
N
.
Preoperative detection of occult endometrial malignancies in endometrial hyperplasia to improve primary surgical therapy: a scoping review of the literature
.
Int J Gynaecol Obstet
.
2022
;
159
(
1
):
21
42
.
53.
Hindman
N
,
Kang
S
,
Fournier
L
,
Lakhman
Y
,
Nougaret
S
,
Reinhold
C
, et al
.
MRI evaluation of uterine masses for risk of leiomyosarcoma: a consensus statement
.
Radiology
.
2023
;
306
(
2
):
e211658
.
54.
Siedhoff
MT
,
Wheeler
SB
,
Rutstein
SE
,
Geller
EJ
,
Doll
KM
,
Wu
JM
, et al
.
Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroid tumors in premenopausal women: a decision analysis
.
Am J Obstet Gynecol
.
2015
;
212
(
5
):
591.e1
8
.
55.
Harris
JA
,
Swenson
CW
,
Uppal
S
,
Kamdar
N
,
Mahnert
N
,
As-Sanie
S
, et al
.
Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation
.
Am J Obstet Gynecol
.
2016
;
214
(
1
):
98.e1
e13
.
You do not currently have access to this content.